Designer BMPs with Altered Receptor Binding Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current designer BMPs have limited diversity and effectiveness in binding to BMP receptors, which restricts their potential for enhanced biological activity and tissue regeneration applications.
Innovation Solution
Development of novel designer BMPs with specific amino acid mutations that alter receptor binding profiles, including mutations in Type I and Type II binding domains, to achieve improved affinity for ALK2, ALK3, ALK6, ActRIIA, ActRIIB, and BMPRIIA receptors, enhancing their osteogenic activity and therapeutic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current designer BMPs are used, then they can bind to BMP receptors, but their binding affinity and biological activity are limited
Solution Approach 1:
The patent applies parameter changes by systematically varying amino acid sequences at specific positions in the BMP protein structure to create a library of designer BMPs with different binding affinities and specificities for various BMP receptors, thereby improving both reliability and adaptability
Solution Approach 2:
The patent applies local quality by making targeted amino acid substitutions at specific binding interface regions of the BMP protein while leaving other regions unchanged, allowing optimization of receptor interaction properties without compromising overall protein structure and function
2Reliability
If novel designer BMPs with specific amino acid mutations are developed, then receptor binding affinity is improved, but protein structure complexity increases
Solution Approach 1:
The patent applies local quality by introducing amino acid mutations only at specific binding domain positions (such as positions 33, 36, 39, 44, 48, 52, 53, 54, 55, 57, 68, 69, 70, 72, 73, 74, 76, 80, 83, 85, 86, 87, 90, 92, 93, 94, 95, 96, 97, 98, 99, 101, 103, 104, 106, 107, 108, 109, 111, 113, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150) that directly contact receptors, rather than throughout the entire protein sequence, thus improving osteogenic activity while controlling complexity
Solution Approach 2:
The patent applies segmentation by dividing the BMP protein into functional domains (N-terminal domain, cystine knot core, C-terminal domain) and independently optimizing amino acid sequences in each domain to achieve desired receptor binding properties without redesigning the entire protein structure
3Reliability
If BMPs with altered receptor binding profiles are created, then therapeutic effectiveness is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent applies parameter changes by optimizing amino acid sequences to improve therapeutic effectiveness while maintaining compatibility with standard recombinant protein expression systems, allowing manufacturing through established biotechnological platforms
Solution Approach 2:
The patent applies copying by using wild-type BMP protein structures as templates and introducing targeted amino acid substitutions to create variant forms, thereby simplifying manufacturing by building upon proven production methods rather than creating entirely new protein architectures
Data Source
AI summary
The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.